Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine Versus Menactra® in Healthy Adolescents/Adults Aged 10-25 Years and Booster Response to MenACWY-TT Vaccine Administered at 5 Years Post-primary Vaccination

NCT00715910 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00715910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00715910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine Versus Menactra® in Healthy Adolescents/Adults Aged 10-25 Years and Booster Response to MenACWY-TT Vaccine Administered at 5 Years Post-primary Vaccination
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2008
Completion date
October 31, 2013
Enrollment
818 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

infections, meningococcal